SKAN Group AG Stock Berne S.E.

Equities

SKAN

CH0013396012

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe 04:12:45 2024-04-19 am EDT 5-day change 1st Jan Change
76.8 CHF 0.00% Intraday chart for SKAN Group AG 0.00% 0.00%
Sales 2024 * 390M 429M Sales 2025 * 462M 508M Capitalization 1.75B 1.93B
Net income 2024 * 40M 44.03M Net income 2025 * 54M 59.44M EV / Sales 2024 * 4.19 x
Net cash position 2024 * 122M 134M Net cash position 2025 * 132M 146M EV / Sales 2025 * 3.51 x
P/E ratio 2024 *
43.2 x
P/E ratio 2025 *
32.2 x
Employees -
Yield 2024 *
0.77%
Yield 2025 *
1.05%
Free-Float 47.23%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 58 08-12-31
Director of Finance/CFO 42 17-12-31
Chief Tech/Sci/R&D Officer 58 22-03-31
Members of the board TitleAgeSince
Director/Board Member 62 21-10-03
Director/Board Member 47 21-10-03
Chief Executive Officer 58 08-12-31
More insiders
SKAN Group AG, former BV Holding AG, is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
78 CHF
Average target price
91.33 CHF
Spread / Average Target
+17.09%
Consensus

Annual profits - Rate of surprise